Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.78

0.0%

Dec 31 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2292)	4/20/2011 5:03:16 PM
From: Jibacoa	of 3722

PRAN was up 23% at its intraday H, but closed up only 13.2% <g> Volume of > 3.6 M was > 2x its ADV.<g> The stock has closed its March UG bigcharts.marketwatch.com PRAN announced today its business strategy to accelerate development of PBT2. The strategy,which now includes Huntington's Disease, should enable PRAN to target market approval for PBT2 several years sooner than previously planned and at less cost. As previously mentioned, PRAN had announced that PBT2 had demonstrated safety and tolerability and reduced Abeta 42, in a PIIa in patients with early AD. It also improved executive function performance in select cognitive tests. Since patients with HD, like those with AD, also have cognitive impairments the company felt that PBT2 could also be of benefit to patients with HD. HD is an uncommon disease and if benefits could be shown with PBT2, it may be able to classify as an 'orphan drug', which could accelerate approval, and lower the costs.<g> There is no ACTAY The stock isn't doing well AHs and has resistance above the $3 level. But with some good news, it could get to retest its March H or even the $6 level.<g> That would be a good % gain from present levels.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next